Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Ionis Pharmaceuticals, Inc.”

202 pharma patents match "Ionis Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 202
Index total 30,257
Page 6 / 9

Quick answer

This filtered view shows 202 pharmaceutical patents matching "Ionis Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

202 results for “Ionis Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 10478449

    2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations

    Ionis Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  2. US 10478448

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  3. US 10472629

    Methods and compositions for modlating apolipoprotein (A) expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  4. US 10443052

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  5. US 10415038

    Compounds and methods for modulating TMPRSS6 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted
  6. US 10407680

    Compounds and methods for reducing Tau expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  7. US 10407678

    Compositions for modulating expression of C9ORF72 antisense transcript

    Ionis Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  8. US 10370659

    Compounds and methods for increasing antisense activity

    Ionis Pharmaceuticals, Inc. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  9. US 10308934

    Compositions for modulating Ataxin 2 expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 4, 2019 · Expires May 30, 2039

    granted
  10. US 10294477

    Compositions and methods for modulating PKK expression

    Ionis Pharmaceuticals, Inc. · Granted May 21, 2019 · Expires May 16, 2039

    granted
  11. US 10280423

    Compositions and methods for modulating complement factor B expression

    Ionis Pharmaceuticals, Inc. · Granted May 7, 2019 · Expires May 2, 2039

    granted
  12. US 10266825

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted
  13. US 10260069

    Selective antisense compounds and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted
  14. US 10221414

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted
  15. US 10202603

    Modulation of huntingtin expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  16. US 10184125

    Modulation of TMPRSS6 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 22, 2019 · Expires Jan 17, 2039

    granted
  17. US 10174318

    Antisense oligonucleotide compositions

    Ionis Pharmaceuticals, Inc. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  18. US 10138482

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  19. US 10100310

    Modulation of prekallikrein (PKK) expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted
  20. US 10098959

    Method for synthesis of reactive conjugate clusters

    Ionis Pharmaceuticals, Inc. · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted
  21. US 10087210

    Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

    Ionis Pharmaceuticals, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted
  22. US 10036019

    Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom

    Ionis Pharmaceuticals, Inc. · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted
  23. US 9994855

    Compositions and methods for modulating growth hormone receptor expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 12, 2018 · Expires Jun 7, 2038

    granted
  24. US 9976138

    Methods and compounds useful in conditions related to repeat expansion

    Ionis Pharmaceuticals, Inc. · Granted May 22, 2018 · Expires May 17, 2038

    granted